The company's lead program, iosH2, is a multi-functional fusion protein that activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors and costimulatory agonists. ImmunOs' portfolio of next-generation immunomodulatory proteins targets diverse immunoregulatory receptors, remodeling the tumor microenvironment to enhance the efficacy of existing immunotherapies. The company's mission is to improve the lives of patients with serious diseases by developing the next generation of novel therapeutics.